Stem definition | Drug id | CAS RN |
---|---|---|
opioid receptor agonists, analgesics, fentanyl derivatives | 2363 | 132875-61-7 |
None
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 0.10 % | Benet LZ, Broccatelli F, Oprea TI |
Vd (Volume of distribution) | 0.40 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 37 mL/min/kg | Lombardo F, Berellini G, Obach RS |
fu (Fraction unbound in plasma) | 0.30 % | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 0.80 hours | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
July 12, 1996 | FDA | MYLAN INSTITUTIONAL | |
Oct. 20, 2006 | PMDA | Janssen Pharmaceutical K.K. |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Anaphylactic shock | 748.04 | 33.93 | 193 | 3745 | 21547 | 56266582 |
Anaphylactic reaction | 321.18 | 33.93 | 129 | 3809 | 58866 | 56229263 |
Cardiac arrest | 143.96 | 33.93 | 84 | 3854 | 86230 | 56201899 |
Bronchospasm | 131.01 | 33.93 | 47 | 3891 | 15622 | 56272507 |
Delayed recovery from anaesthesia | 122.89 | 33.93 | 24 | 3914 | 734 | 56287395 |
Circulatory collapse | 104.27 | 33.93 | 43 | 3895 | 20760 | 56267369 |
Bradycardia | 97.64 | 33.93 | 60 | 3878 | 67444 | 56220685 |
Hypotension | 94.32 | 33.93 | 101 | 3837 | 250407 | 56037722 |
Neuromuscular block prolonged | 81.54 | 33.93 | 16 | 3922 | 501 | 56287628 |
Tachycardia | 79.67 | 33.93 | 63 | 3875 | 105813 | 56182316 |
Hyperthermia malignant | 75.59 | 33.93 | 16 | 3922 | 735 | 56287394 |
Serotonin syndrome | 69.84 | 33.93 | 35 | 3903 | 26455 | 56261674 |
Blood pressure decreased | 64.42 | 33.93 | 44 | 3894 | 59006 | 56229123 |
Exposure during pregnancy | 58.36 | 33.93 | 59 | 3879 | 136283 | 56151846 |
Anaphylactoid reaction | 55.34 | 33.93 | 17 | 3921 | 3489 | 56284640 |
Stress cardiomyopathy | 54.90 | 33.93 | 21 | 3917 | 8315 | 56279814 |
Patent ductus arteriosus | 53.34 | 33.93 | 17 | 3921 | 3934 | 56284195 |
Anaphylactoid shock | 50.66 | 33.93 | 10 | 3928 | 323 | 56287806 |
Pulseless electrical activity | 47.35 | 33.93 | 18 | 3920 | 7006 | 56281123 |
Hyperreflexia | 44.79 | 33.93 | 16 | 3922 | 5234 | 56282895 |
Clonus | 44.14 | 33.93 | 15 | 3923 | 4234 | 56283895 |
Premature delivery | 44.09 | 33.93 | 26 | 3912 | 27034 | 56261095 |
Premature baby | 40.90 | 33.93 | 22 | 3916 | 19183 | 56268946 |
Ventricular tachycardia | 40.65 | 33.93 | 21 | 3917 | 16880 | 56271249 |
Dyskinesia | 39.80 | 33.93 | 25 | 3913 | 29083 | 56259046 |
Diabetes insipidus | 39.24 | 33.93 | 12 | 3926 | 2425 | 56285704 |
Toxic epidermal necrolysis | 38.07 | 33.93 | 22 | 3916 | 22020 | 56266109 |
Drug interaction | 38.02 | 33.93 | 59 | 3879 | 209696 | 56078433 |
Fatigue | 34.01 | 33.93 | 7 | 3931 | 788545 | 55499584 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Anaphylactic shock | 514.71 | 32.08 | 148 | 3736 | 13997 | 31679463 |
Anaphylactic reaction | 226.68 | 32.08 | 97 | 3787 | 29456 | 31664004 |
Cardiac arrest | 149.38 | 32.08 | 107 | 3777 | 88955 | 31604505 |
Hyperthermia malignant | 139.34 | 32.08 | 35 | 3849 | 1949 | 31691511 |
Hypotension | 120.64 | 32.08 | 136 | 3748 | 204482 | 31488978 |
Delayed recovery from anaesthesia | 110.15 | 32.08 | 24 | 3860 | 713 | 31692747 |
Neuromuscular block prolonged | 103.31 | 32.08 | 21 | 3863 | 442 | 31693018 |
Bradycardia | 99.62 | 32.08 | 76 | 3808 | 69251 | 31624209 |
Trigemino-cardiac reflex | 89.18 | 32.08 | 16 | 3868 | 167 | 31693293 |
Bronchospasm | 87.17 | 32.08 | 36 | 3848 | 9936 | 31683524 |
Propofol infusion syndrome | 85.66 | 32.08 | 20 | 3864 | 815 | 31692645 |
Blood pressure decreased | 80.87 | 32.08 | 58 | 3826 | 48033 | 31645427 |
Toxic epidermal necrolysis | 78.08 | 32.08 | 41 | 3843 | 19483 | 31673977 |
Airway complication of anaesthesia | 72.25 | 32.08 | 13 | 3871 | 138 | 31693322 |
Ventricular fibrillation | 68.10 | 32.08 | 37 | 3847 | 18811 | 31674649 |
Drug interaction | 64.11 | 32.08 | 101 | 3783 | 208442 | 31485018 |
Kounis syndrome | 63.18 | 32.08 | 19 | 3865 | 2065 | 31691395 |
Diabetes insipidus | 59.48 | 32.08 | 19 | 3865 | 2521 | 31690939 |
Hypoventilation | 55.92 | 32.08 | 19 | 3865 | 3055 | 31690405 |
Drug reaction with eosinophilia and systemic symptoms | 54.57 | 32.08 | 38 | 3846 | 29980 | 31663480 |
Seizure like phenomena | 53.10 | 32.08 | 13 | 3871 | 649 | 31692811 |
Cardio-respiratory arrest | 45.84 | 32.08 | 43 | 3841 | 51683 | 31641777 |
Circulatory collapse | 45.54 | 32.08 | 29 | 3855 | 19715 | 31673745 |
Arteriospasm coronary | 45.35 | 32.08 | 16 | 3868 | 2875 | 31690585 |
Anaesthetic complication neurological | 39.84 | 32.08 | 9 | 3875 | 316 | 31693144 |
Recurrence of neuromuscular blockade | 38.96 | 32.08 | 8 | 3876 | 177 | 31693283 |
Anaphylactoid shock | 38.67 | 32.08 | 9 | 3875 | 361 | 31693099 |
Sinus arrest | 38.34 | 32.08 | 12 | 3872 | 1489 | 31691971 |
Erythema | 38.05 | 32.08 | 48 | 3836 | 80357 | 31613103 |
Neuromuscular blockade | 36.50 | 32.08 | 8 | 3876 | 244 | 31693216 |
Status epilepticus | 36.19 | 32.08 | 21 | 3863 | 12085 | 31681375 |
Rhabdomyolysis | 35.02 | 32.08 | 41 | 3843 | 63540 | 31629920 |
Anaphylactoid reaction | 34.33 | 32.08 | 12 | 3872 | 2097 | 31691363 |
Tachycardia | 33.70 | 32.08 | 44 | 3840 | 76163 | 31617297 |
Death | 33.33 | 32.08 | 3 | 3881 | 360566 | 31332894 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Anaphylactic shock | 1214.35 | 25.77 | 339 | 7481 | 32151 | 70888473 |
Anaphylactic reaction | 533.02 | 25.77 | 226 | 7594 | 74748 | 70845876 |
Cardiac arrest | 271.78 | 25.77 | 186 | 7634 | 159648 | 70760976 |
Delayed recovery from anaesthesia | 217.09 | 25.77 | 47 | 7773 | 1510 | 70919114 |
Bronchospasm | 199.75 | 25.77 | 80 | 7740 | 22712 | 70897912 |
Hypotension | 192.51 | 25.77 | 229 | 7591 | 404152 | 70516472 |
Hyperthermia malignant | 192.03 | 25.77 | 47 | 7773 | 2614 | 70918010 |
Bradycardia | 167.77 | 25.77 | 126 | 7694 | 124489 | 70796135 |
Neuromuscular block prolonged | 167.40 | 25.77 | 35 | 7785 | 948 | 70919676 |
Circulatory collapse | 136.12 | 25.77 | 70 | 7750 | 35404 | 70885220 |
Blood pressure decreased | 130.84 | 25.77 | 96 | 7724 | 91419 | 70829205 |
Trigemino-cardiac reflex | 117.91 | 25.77 | 21 | 7799 | 235 | 70920389 |
Tachycardia | 99.43 | 25.77 | 104 | 7716 | 158442 | 70762182 |
Toxic epidermal necrolysis | 99.24 | 25.77 | 59 | 7761 | 39498 | 70881126 |
Diabetes insipidus | 96.60 | 25.77 | 31 | 7789 | 4640 | 70915984 |
Propofol infusion syndrome | 92.28 | 25.77 | 24 | 7796 | 1705 | 70918919 |
Drug interaction | 90.07 | 25.77 | 155 | 7665 | 381286 | 70539338 |
Airway complication of anaesthesia | 89.66 | 25.77 | 18 | 7802 | 396 | 70920228 |
Anaphylactoid reaction | 86.49 | 25.77 | 29 | 7791 | 4978 | 70915646 |
Kounis syndrome | 84.56 | 25.77 | 26 | 7794 | 3385 | 70917239 |
Anaphylactoid shock | 84.06 | 25.77 | 19 | 7801 | 745 | 70919879 |
Ventricular fibrillation | 82.86 | 25.77 | 46 | 7774 | 27065 | 70893559 |
Pulseless electrical activity | 71.49 | 25.77 | 33 | 7787 | 13182 | 70907442 |
Hypoventilation | 67.81 | 25.77 | 26 | 7794 | 6556 | 70914068 |
Recurrence of neuromuscular blockade | 66.02 | 25.77 | 13 | 7807 | 258 | 70920366 |
Erythema | 63.38 | 25.77 | 93 | 7727 | 199470 | 70721154 |
Fatigue | 61.50 | 25.77 | 9 | 7811 | 824310 | 70096314 |
Stress cardiomyopathy | 60.86 | 25.77 | 27 | 7793 | 9835 | 70910789 |
Serotonin syndrome | 59.69 | 25.77 | 44 | 7776 | 42070 | 70878554 |
Ventricular tachycardia | 58.36 | 25.77 | 41 | 7779 | 36382 | 70884242 |
Rhabdomyolysis | 54.96 | 25.77 | 60 | 7760 | 95700 | 70824924 |
Post procedural complication | 52.92 | 25.77 | 32 | 7788 | 22049 | 70898575 |
Upper airway obstruction | 50.34 | 25.77 | 14 | 7806 | 1282 | 70919342 |
Sinus arrest | 49.17 | 25.77 | 17 | 7803 | 3198 | 70917426 |
Respiratory depression | 47.02 | 25.77 | 31 | 7789 | 24800 | 70895824 |
Neuromuscular blockade | 45.89 | 25.77 | 11 | 7809 | 559 | 70920065 |
Clonus | 44.68 | 25.77 | 19 | 7801 | 6249 | 70914375 |
Seizure like phenomena | 42.20 | 25.77 | 13 | 7807 | 1702 | 70918922 |
Death | 41.84 | 25.77 | 4 | 7816 | 510057 | 70410567 |
Cardio-respiratory arrest | 41.07 | 25.77 | 53 | 7767 | 100624 | 70820000 |
Anaesthetic complication | 40.55 | 25.77 | 14 | 7806 | 2622 | 70918002 |
Pain | 40.19 | 25.77 | 10 | 7810 | 628806 | 70291818 |
Arteriospasm coronary | 38.80 | 25.77 | 17 | 7803 | 6007 | 70914617 |
Arthralgia | 38.63 | 25.77 | 5 | 7815 | 503385 | 70417239 |
Drug reaction with eosinophilia and systemic symptoms | 37.97 | 25.77 | 39 | 7781 | 57974 | 70862650 |
Urticaria | 36.66 | 25.77 | 65 | 7755 | 162984 | 70757640 |
Anaesthetic complication neurological | 35.67 | 25.77 | 9 | 7811 | 566 | 70920058 |
Nausea | 34.84 | 25.77 | 26 | 7794 | 852062 | 70068562 |
Respiratory arrest | 33.04 | 25.77 | 35 | 7785 | 53898 | 70866726 |
Blood pressure immeasurable | 32.50 | 25.77 | 11 | 7809 | 1941 | 70918683 |
Procedural hypotension | 32.42 | 25.77 | 11 | 7809 | 1955 | 70918669 |
Hyperreflexia | 32.36 | 25.77 | 16 | 7804 | 7426 | 70913198 |
Type I hypersensitivity | 32.31 | 25.77 | 13 | 7807 | 3719 | 70916905 |
Postoperative delirium | 32.16 | 25.77 | 7 | 7813 | 230 | 70920394 |
Electrocardiogram ST segment elevation | 32.04 | 25.77 | 16 | 7804 | 7588 | 70913036 |
Fall | 30.49 | 25.77 | 6 | 7814 | 444090 | 70476534 |
Subcutaneous emphysema | 30.07 | 25.77 | 10 | 7810 | 1672 | 70918952 |
Oxygen saturation decreased | 29.56 | 25.77 | 49 | 7771 | 116380 | 70804244 |
Dyskinesia | 29.42 | 25.77 | 29 | 7791 | 41045 | 70879579 |
Capillary nail refill test abnormal | 28.86 | 25.77 | 5 | 7815 | 47 | 70920577 |
Acute generalised exanthematous pustulosis | 28.61 | 25.77 | 19 | 7801 | 15378 | 70905246 |
Exposure during pregnancy | 27.96 | 25.77 | 41 | 7779 | 87676 | 70832948 |
Respiratory acidosis | 27.50 | 25.77 | 16 | 7804 | 10265 | 70910359 |
Pulmonary alveolar haemorrhage | 27.38 | 25.77 | 16 | 7804 | 10353 | 70910271 |
Hypoxic-ischaemic encephalopathy | 26.79 | 25.77 | 14 | 7806 | 7294 | 70913330 |
Dizziness | 26.65 | 25.77 | 9 | 7811 | 464132 | 70456492 |
Prinzmetal angina | 26.51 | 25.77 | 9 | 7811 | 1603 | 70919021 |
Shock | 26.13 | 25.77 | 27 | 7793 | 40398 | 70880226 |
Torsade de pointes | 25.82 | 25.77 | 19 | 7801 | 18097 | 70902527 |
None
Source | Code | Description |
---|---|---|
ATC | N01AH06 | NERVOUS SYSTEM ANESTHETICS ANESTHETICS, GENERAL Opioid anesthetics |
MeSH PA | D000700 | Analgesics |
MeSH PA | D000701 | Analgesics, Opioid |
MeSH PA | D002491 | Central Nervous System Agents |
MeSH PA | D002492 | Central Nervous System Depressants |
MeSH PA | D009294 | Narcotics |
MeSH PA | D018373 | Peripheral Nervous System Agents |
MeSH PA | D018689 | Sensory System Agents |
CHEBI has role | CHEBI:35482 | narcotic analgesic |
CHEBI has role | CHEBI:35717 | hypnotics |
CHEBI has role | CHEBI:38877 | intravenous anesthetics |
CHEBI has role | CHEBI:55322 | mu-opioid agonists |
FDA MoA | N0000175684 | Full Opioid Agonists |
FDA EPC | N0000175690 | Opioid Agonist |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
General anesthesia | indication | 50697003 | |
Local anesthesia | indication | 386761002 | |
Acute postoperative pain | indication | 107401000119105 | |
Low blood pressure | contraindication | 45007003 | |
Bradycardia | contraindication | 48867003 | |
Decreased respiratory function | contraindication | 80954004 |
None
None
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 7.07 | Basic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Mu-type opioid receptor | GPCR | AGONIST | WOMBAT-PK | CHEMBL | |||||
Mu-type opioid receptor | GPCR | IC50 | 9.22 | CHEMBL |
ID | Source |
---|---|
4024040 | VUID |
N0000022045 | NUI |
D01177 | KEGG_DRUG |
4020990 | VANDF |
4024040 | VANDF |
C0246631 | UMLSCUI |
CHEBI:8802 | CHEBI |
CHEMBL1005 | ChEMBL_ID |
DB00899 | DRUGBANK_ID |
CHEMBL1201120 | ChEMBL_ID |
D000077208 | MESH_DESCRIPTOR_UI |
60815 | PUBCHEM_CID |
7292 | IUPHAR_LIGAND_ID |
6924 | INN_ID |
132539-07-2 | SECONDARY_CAS_RN |
P10582JYYK | UNII |
236540 | RXNORM |
181723 | MMSL |
186043 | MMSL |
5415 | MMSL |
d04034 | MMSL |
006250 | NDDF |
006251 | NDDF |
108376001 | SNOMEDCT_US |
108379008 | SNOMEDCT_US |
386839004 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
REMIFENTANIL HYDROCHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9391 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 1 mg | INTRAVENOUS | ANDA | 27 sections |
REMIFENTANIL HYDROCHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9392 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 2 mg | INTRAVENOUS | ANDA | 27 sections |
REMIFENTANIL HYDROCHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9393 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 5 mg | INTRAVENOUS | ANDA | 27 sections |
Remifentanil Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63323-723 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 1 mg | INTRAVENOUS | ANDA | 30 sections |
Remifentanil Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63323-723 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 1 mg | INTRAVENOUS | ANDA | 30 sections |
Remifentanil Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63323-724 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 1 mg | INTRAVENOUS | ANDA | 30 sections |
Remifentanil Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63323-725 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 1 mg | INTRAVENOUS | ANDA | 30 sections |
Ultiva | HUMAN PRESCRIPTION DRUG LABEL | 1 | 67457-198 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 1 mg | INTRAVENOUS | NDA | 30 sections |
Ultiva | HUMAN PRESCRIPTION DRUG LABEL | 1 | 67457-912 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 1 mg | INTRAVENOUS | NDA | 30 sections |
Ultiva | HUMAN PRESCRIPTION DRUG LABEL | 1 | 67457-913 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 1 mg | INTRAVENOUS | NDA | 30 sections |
Ultiva | HUMAN PRESCRIPTION DRUG LABEL | 1 | 67457-914 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 1 mg | INTRAVENOUS | NDA | 30 sections |
REMIFENTANIL HYDROCHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 68475-505 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 1 mg | INTRAVENOUS | ANDA | 27 sections |
REMIFENTANIL HYDROCHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 68475-506 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 2 mg | INTRAVENOUS | ANDA | 27 sections |
REMIFENTANIL HYDROCHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 68475-507 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 5 mg | INTRAVENOUS | ANDA | 27 sections |